FOLH1 and Familial prostate cancer: Weber et al. administered MKC1106-PP, an immunotherapy regimen that co-targets PRAME, PSMA, and 2 peptides (E-PRA and E-PSM from PRAME and PSMA, respectively) for 10 patients with prostate cancer.